Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2 CYP2C9 CYP2D6 and CYP3A Substrates (Caffeine Warfarin Dextromethorphan and Midazolam) in Cancer Patients
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib.
Description
The purpose of this study is to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Neoplasm Metastasis
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 1602868870 (I3Y-MC-JPCB)
